| Literature DB >> 27748454 |
J M G van Bergen1, X Li2,3, J Hua2,3, S J Schreiner1,4, S C Steininger1,4, F C Quevenco1, M Wyss5, A F Gietl1,4, V Treyer1,6, S E Leh1,4, F Buck6, R M Nitsch1,4, K P Pruessmann5, P C M van Zijl2,3, C Hock1, P G Unschuld1,4.
Abstract
Quantitative Susceptibility Mapping (QSM) MRI at 7 Tesla and 11-Carbon Pittsburgh-Compound-B PET were used for investigating the relationship between brain iron and Amyloid beta (Aβ) plaque-load in a context of increased risk for Alzheimer's disease (AD), as reflected by the Apolipoprotein E ε4 (APOE-e4) allele and mild cognitive impairment (MCI) in elderly subjects. Carriers of APOE-e4 with normal cognition had higher cortical Aβ-plaque-load than non-carriers. In MCI an association between APOE-e4 and higher Aβ-plaque-load was observable both for cortical and subcortical brain-regions. APOE-e4 and MCI was also associated with higher cortical iron. Moreover, cerebral iron significantly affected functional coupling, and was furthermore associated with increased Aβ-plaque-load (R2-adjusted = 0.80, p < 0.001) and APOE-e4 carrier status (p < 0.001) in MCI. This study confirms earlier reports on an association between increased brain iron-burden and risk for neurocognitive dysfunction due to AD, and indicates that disease-progression is conferred by spatial colocalization of brain iron deposits with Aβ-plaques.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27748454 PMCID: PMC5066274 DOI: 10.1038/srep35514
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic data and clinical assessment scores for control subjects with normal cognition and MCI subjects at time of inclusion in the study.
| Controls | MCI | |
|---|---|---|
| N (F/M) | 8/14 | 5/10 |
| Age (years) | 71.91 ± 5.25 | 75.27 ± 7.63 |
| Education (years) | 13.64 ± 2.56 | 15.2 ± 3.51 |
| PiB-PET retention | 1.16 ± 0.08 | 1.5 ± 0.17** |
| APOE-e4 positive | 7 (31%) | 6 (40%) |
| MMSE | 29.27 ± 0.70 | 28.61 ± 1.65 |
| MOCA | 27.36 ± 1.30 | 24.44 ± 2.17** |
| VLMT: immediate recall | 11.59 ± 2.22 | 7.11 ± 4.00*** |
| VLMT: delayed recall | 11.41 ± 2.94 | 6.83 ± 4.29*** |
| VLMT: recognition | 12.73 ± 2.31 | 7.78 ± 5.79** |
| Boston Naming Test | 14.68 ± 0.48 | 13.94 ± 1.26* |
| WMS: pairs learning | 14.76 ± 4.28 | 10.65 ± 4.72** |
| WMS: pairs recall | 5.52 ± 1.49 | 3.88 ± 1.75** |
| Verbal Working Memory | 6.32 ± 1.99 | 5.44 ± 1.42 |
| Trail Making Test ratio | 2.58 ± 0.74 | 2.6 ± 1.24 |
Data are presented as mean ± standard deviation. APOE-e4 status presented as N (percentage of group). Age and Education are in years. *Significant difference between controls and MCI with p < 0.05, **p < 0.01, ***p < 0.001.
Figure 1Example images for a control subject (left) and MCI subject (right).
The top row shows PiB-PET images of Aβ-plaque-load in gray matter, which is highly increased in the frontal regions in the MCI subject, the signal in the white matter is non-specific to Aβ-plaque-load and is also observed in the control subject. The bottom row shows QSM maps of the same slices indicating regions with high iron load such as the basal ganglia.
Changes in corrected volume and susceptibility (referenced to CSF) between controls and MCI.
| Corrected volume (ml) Mean ± STE | χ (ppb) Mean ± STE | |||
|---|---|---|---|---|
| Controls | MCI | Controls | MCI | |
| Amygdala | 4.03 ± 0.09 | 3.60 ± 0.15*** | −16.6 ± 2.3 | −17.4 ± 2.3 |
| Nucleus Acc | 1.76 ± 0.07 | 1.84 ± 0.10 | 11.8 ± 3.7 | 11.8 ± 5.5 |
| Hippocampus | 8.62 ± 0.18 | 7.55 ± 0.22*** | −1.3 ± 1.7 | −0.6 ± 2.9 |
| Entorhinal Ctx | 2.15 ± 0.13 | 2.01 ± 0.15 | 23.4 ± 3.8 | 25.8 ± 3.3 |
| Thalamus | 13.88 ± 0.19 | 12.83 ± 0.40*** | −7.7 ± 1.8 | −8.9 ± 1.8 |
| Caudate Nucleus | 9.53 ± 0.24 | 9.31 ± 0.30 | 41.4 ± 4.2 | 38.2 ± 3.7 |
| Putamen | 10.11 ± 0.27 | 8.92 ± 0.43*** | 63.6 ± 4.4 | 61.2 ± 4.3 |
| Globus Pallidus | 3.50 ± 0.07 | 3.35 ± 0.09 | 104.5 ± 4.9 | 99.3 ± 5.0 |
| Frontal Ctx | 16.56 ± 1.98 | 16.13 ± 2.36 | 2.1 ± 1.8 | 2.6 ± 2.2 |
| Temporal Ctx | 23.24 ± 2.40 | 22.13 ± 2.77 | 0.3 ± 1.6 | 2.1 ± 2.1 |
| Parietal Ctx | 21.63 ± 1.13 | 21.23 ± 1.32 | 4.3 ± 1.6 | 4.0 ± 1.8 |
| Occipital Ctx | 18.76 ± 2.51 | 18.38 ± 2.93 | 3.6 ± 1.8 | 3.8 ± 2.1 |
Ctx = Cortex. Data are presented as mean ± standard error (STE). ***Significant difference between controls and MCI with p < 0.001.
Quantitative magnetic susceptibility (χ in ppb referenced to CSF) and PiB-PET retention (SUVR) separated by APOE-e4 status within the two groups.
| Iron load (χ, ppb) Mean ± STE | Aβ-plaque-load (PiB-PET, SUVR) Mean ± STE | |||||
|---|---|---|---|---|---|---|
| APOE-e4 - | APOE-e4 + | APOE-e4 - | APOE-e4 + | |||
| A) Controls | ||||||
| Amygdala | −17.2 ± 2.5 | −15.3 ± 2.2 | 0.19 | 1.19 ± 0.02 | 1.19 ± 0.02 | 0.02 |
| Nucleus Acc | 12.1 ± 4.1 | 11.2 ± 3.2 | 0.06 | 1.17 ± 0.02 | 1.23 ± 0.03 | 0.64* |
| Hippocampus | −1.4 ± 1.7 | −1.2 ± 2.1 | 0.02 | 1.25 ± 0.02 | 1.31 ± 0.02 | 0.70* |
| Entorhinal Ctx | 22.6 ± 5.1 | 25.0 ± 2.6 | 0.15 | 1.08 ± 0.02 | 1.14 ± 0.01 | 0.92** |
| Thalamus | −6.5 ± 1.9 | −10.5 ± 1.4 | 0.55 | 1.48 ± 0.04 | 1.48 ± 0.04 | 0.01 |
| Caudate Nucleus | 46.0 ± 3.7 | 31.5 ± 5.5 | 0.75* | 1.26 ± 0.03 | 1.28 ± 0.03 | 0.23 |
| Putamen | 67.2 ± 4.3 | 55.9 ± 5.3 | 0.56 | 1.33 ± 0.02 | 1.36 ± 0.01 | 0.46 |
| Globus Pallidus | 106.4 ± 5.0 | 100.4 ± 5.7 | 0.26 | 1.45 ± 0.02 | 1.50 ± 0.04 | 0.34 |
| Frontal Ctx | 2.6 ± 1.9 | 1.1 ± 2.0 | 0.18 | 1.02 ± 0.03 | 1.13 ± 0.04 | 0.69*** |
| Temporal Ctx | 0.7 ± 1.6 | −0.6 ± 2.0 | 0.17 | 1.04 ± 0.02 | 1.10 ± 0.04 | 0.48*** |
| Parietal Ctx | 4.1 ± 1.6 | 2.7 ± 1.8 | 0.25 | 0.99 ± 0.02 | 1.15 ± 0.05 | 1.07*** |
| Occipital Ctx | 4.0 ± 1.9 | 2.9 ± 1.8 | 0.14 | 1.14 ± 0.03 | 1.19 ± 0.04 | 0.42** |
| B) MCI | ||||||
| Amygdala | −17.5 ± 1.8 | −17.2 ± 2.6 | 0.04 | 1.07 ± 0.02 | 1.54 ± 0.03 | 4.01*** |
| Nucleus Acc | 8.2 ± 4.9 | 17.3 ± 4.7 | 0.44 | 1.16 ± 0.02 | 2.41 ± 0.07 | 7.00*** |
| Hippocampus | −2.0 ± 2.0 | 1.5 ± 3.5 | 0.31 | 1.14 ± 0.03 | 1.42 ± 0.03 | 2.55*** |
| Entorhinal Ctx | 23.1 ± 3.4 | 30.0 ± 2.5 | 0.56 | 1.02 ± 0.03 | 1.31 ± 0.03 | 2.80*** |
| Thalamus | −9.1 ± 1.4 | −8.5 ± 2.1 | 0.07 | 1.46 ± 0.02 | 1.80 ± 0.06 | 1.95*** |
| Caudate Nucleus | 32.7 ± 2.0 | 46.3 ± 4.5 | 1.03** | 1.24 ± 0.04 | 2.13 ± 0.09 | 3.40*** |
| Putamen | 58.6 ± 3.7 | 65.2 ± 4.0 | 0.41 | 1.29 ± 0.01 | 2.23 ± 0.05 | 7.29*** |
| Globus Pallidus | 96.4 ± 3.3 | 103.5 ± 6.3 | 0.36 | 1.41 ± 0.03 | 1.92 ± 0.06 | 2.86*** |
| Frontal Ctx | 0.1 ± 1.6 | 6.3 ± 2.2 | 0.78*** | 0.98 ± 0.05 | 1.95 ± 0.10 | 3.32*** |
| Temporal Ctx | 0.0 ± 1.8 | 5.2 ± 1.8 | 0.67*** | 1.03 ± 0.02 | 1.73 ± 0.07 | 3.50*** |
| Parietal Ctx | 1.3 ± 1.2 | 8.1 ± 1.8 | 1.11*** | 1.00 ± 0.03 | 1.87 ± 0.09 | 3.60*** |
| Occipital Ctx | 1.5 ± 1.4 | 7.2 ± 2.4 | 0.71*** | 1.13 ± 0.02 | 1.59 ± 0.08 | 2.20*** |
*Significant difference between APOE-e4 positive and negative with p < 0.05, **p < 0.01, ***p < 0.001. d indicates effect sizes (Cohen's d).
Figure 2Regions that show significant increased iron associated coupling (T(1,7) above 10.99 indicating p-FDR-corrected <0.001) with the medial prefrontal cortex (MPFC) in subjects with MCI.
Figure 3Average Cortical PiB-PET Retention and Cortical Susceptibility of all MCI subjects (top) for the region with significantly increased coupling shown in Fig. 2.
The dotted line indicates the median split of the Cortical PiB-PET Retention of all subjects in the study, the trend line is indicated in gray (p < 0.001, Spearman’s rho = 0.86, R2-adjusted = 0.80). Average Cortical PiB-PET Retention and Cortical Susceptibility for MCI subjects and controls when split based on APOE-e4 status (bottom), the error bars represent standard error. *** Significant difference between APOE-e4 positive and negative with p < 0.001.